Pharmaxis Doses First Patient in Phase 2 Bone Marrow Cancer Trial

13th Oct 21

Release Date: 13/10/2021 11:00am

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has commenced dosing in the phase 2 clinical trial studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis. 

Read full media release - pdf

Categories: News and Media